Y-mAbs Showcases GD2-SADA Pharmacokinetics at Key Event
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), a pioneering biopharmaceutical entity devoted to groundbreaking cancer therapies, recently highlighted its innovative research on GD2-SADA at an industry-leading conference. This presentation was part of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Mid-Winter and American College of Nuclear Medicine (ACNM) Annual Meeting.
Understanding the GD2-SADA Presentation
The pivotal poster, titled "Preclinical and Translational Pharmacokinetics of GD2-SADA, a Self-Assembling and Disassembling (SADA) Bispecific Fusion Protein for Pretargeted Radioimmunotherapy (PRIT)," elaborated on critical aspects such as plasma levels of GD2-SADA over various dosages and timeframes. This poster also discusses how GD2-SADA tetramers and monomers interact in a controlled laboratory environment.
Insights from the Chief Development Officer
Norman LaFrance, M.D., Chief Development Officer at Y-mAbs, expressed optimism regarding the implications of their research: "The human pharmacokinetic model developed for GD2-SADA has shaped the design of our ongoing first-in-human Phase 1 Trial (Trial 1001). We are excited to enhance this model with actual patient data from the trial and expand our research into other upcoming SADA PRIT trials."
Key Details from the Event
Specifics from the abstract presented underline the significance of their findings. Here are the essential details:
- Abstract Title: Preclinical and translational pharmacokinetics of GD2-SADA, a self-assembling and disassembling (SADA) bispecific fusion protein for pretargeted radioimmunotherapy (PRIT)
- Format: Poster Presentation, ID: A2578
- Date and Time: A noted time on the agenda highlights the importance of this research on future treatment pathways.
Collaboration with Memorial Sloan Kettering Cancer Center
This innovative approach stems from a collaborative partnership with Memorial Sloan Kettering Cancer Center (MSK), where Dr. Nai-Kong Cheung pioneered the SADA technology. The exclusive licensing of this technology to Y-mAbs embodies a mutual commitment to advancing cancer treatment. Dr. Cheung's involvement has solidified the foundation upon which GD2-SADA is being developed.
The Mission of Y-mAbs Therapeutics
Y-mAbs is dedicated to progressing the field of biopharmaceuticals. The company's focus on developing and commercializing novel radioimmunotherapies and antibody-based therapies reflects their strategic vision. A strong aspect of their portfolio includes the investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and their innovative bispecific antibodies generated via the Y-BiClone platform.
About GD2-SADA PRIT
GD2-SADA functions as a bispecific fusion protein that binds with precision to the glycolipid GD2. This unique binding facilitates its innovative approach in radiotherapy, where the first stage primarily involves the infusion of non-radiolabeled GD2-SADA tetramers that target GD2-expressing tumors while ensuring that excess protein is efficiently cleared through the kidneys. A subsequent administration introduces a radioactive component that targets tumor cells directly, enhancing localized irradiation.
Frequently Asked Questions
What is GD2-SADA?
GD2-SADA is a bispecific fusion protein developed for pretreatment in radioimmunotherapy, specifically targeting GD2-expressing tumors.
What type of data was presented at the conference?
The presentation showcased preclinical and translational pharmacokinetics data related to GD2-SADA.
Who is involved in the development of GD2-SADA?
The technology was developed by Dr. Nai-Kong Cheung at Memorial Sloan Kettering Cancer Center and is exclusively licensed to Y-mAbs.
What is the significance of the Phase 1 Trial (Trial 1001)?
This trial is pivotal for collecting human pharmacokinetic data that will refine the understanding and use of GD2-SADA in treatments.
How does Y-mAbs support cancer treatment advancements?
Y-mAbs focuses on pioneering biopharmaceutical products, particularly in developing antibody-based therapies and innovative treatment platforms.
